Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia.

Authors

Asmaa El-Heneidy, Keith Grimwood, Mohana Rajmokan, Ashish Shrestha, Stephen Lambert, Robert Ware

Published in

Communicable diseases intelligence (2018). Volume 50. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Nirsevimab, a long-acting monoclonal antibody with activity against respiratory syncytial virus (RSV), was introduced into the Queensland paediatric RSV prevention program in 2024. Using Queensland Notifiable Conditions Register (NoCS) data, we found that the infant cohort eligible for the nirsevimab program had lower RSV hospitalisation rates than comparable pre-program cohorts. The population-level impact of nirsevimab was greatest during the first month of life (incidence rate ratio [IRR]: 0.22; 95% confidence interval [95% CI]: 0.16-0.31; representing a 78% reduction in hospitalisation rate), with its magnitude gradually declining thereafter until nine months of age (IRR: 0.77; 95% CI: 0.62-0.96; a 23% reduction), following which the impact of nirsevimab on hospitalisation rate, with increasing age of the infant or child, was no longer statistically significant. An interrupted time-series analysis demonstrated an immediate 63% reduction in RSV hospitalisations following nirsevimab's introduction (IRR: 0.37; 95% CI: 0.23-0.60), showing a substantial population-level impact of the program in Queensland, Australia.

PMID:
42896226
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.